S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.87 (-0.76%)
CGC   14.48 (-0.82%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.19 (+1.15%)
F   6.74 (+1.51%)
ACB   5.27 (+1.93%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.55 (+0.22%)
BAC   23.72 (+1.98%)
BA   147.89 (-2.18%)
S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.87 (-0.76%)
CGC   14.48 (-0.82%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.19 (+1.15%)
F   6.74 (+1.51%)
ACB   5.27 (+1.93%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.55 (+0.22%)
BAC   23.72 (+1.98%)
BA   147.89 (-2.18%)
S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.87 (-0.76%)
CGC   14.48 (-0.82%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.19 (+1.15%)
F   6.74 (+1.51%)
ACB   5.27 (+1.93%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.55 (+0.22%)
BAC   23.72 (+1.98%)
BA   147.89 (-2.18%)
S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.87 (-0.76%)
CGC   14.48 (-0.82%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.19 (+1.15%)
F   6.74 (+1.51%)
ACB   5.27 (+1.93%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.55 (+0.22%)
BAC   23.72 (+1.98%)
BA   147.89 (-2.18%)
Log in
CVE:HLS

HLS Therapeutics Price Target, Predictions & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume49,300 shs
Average Volume97,793 shs
Market CapitalizationC$384.86 million
P/E RatioN/A
Dividend Yield1.46%
BetaN/A

Analyst Ratings

HLS Therapeutics (CVE:HLS) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for HLS Therapeutics in the last 12 months. Their average twelve-month price target is C$29.00The high price target for HLS is C$29.00 and the low price target for HLS is C$29.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
HLS Consensus Rating: BuyBuyBuyBuy
HLS Consensus Rating Score: 3.003.003.003.00
HLS Analyst Ratings: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
HLS Consensus Price Target: C$29.00C$29.00C$28.50C$30.00
HLS Price Target Upside: N/AN/AN/AN/A

HLS Therapeutics (CVE:HLS) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HLS Therapeutics (CVE:HLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/7/2020Canaccord GenuityBoost Price TargetC$28.50 ➝ C$29.00
1/2/2020Clarus SecuritiesReiterated RatingSpeculative Buy ➝ Buy
10/4/2019Bloom BurtonUpgradeHold ➝ Buy
(Data available from 9/24/2018 forward)
This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.